Solid Biosciences (SLDB) Competitors

Solid Biosciences logo
$6.23 -0.25 (-3.86%)
Closing price 04:00 PM Eastern
Extended Trading
$6.24 +0.01 (+0.16%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SLDB vs. DYN, TLX, ZLAB, ACAD, and IDYA

Should you buy Solid Biosciences stock or one of its competitors? Solid Biosciences's main competitors and comparable companies include Dyne Therapeutics (DYN), Telix Pharmaceuticals (TLX), Zai Lab (ZLAB), ACADIA Pharmaceuticals (ACAD), and IDEAYA Biosciences (IDYA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Solid Biosciences compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Solid Biosciences (NASDAQ:SLDB) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

Dyne Therapeutics presently has a consensus target price of $31.29, indicating a potential upside of 95.29%. Solid Biosciences has a consensus target price of $20.00, indicating a potential upside of 221.03%. Given Solid Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Solid Biosciences is more favorable than Dyne Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dyne Therapeutics
2 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.69
Solid Biosciences
1 Sell rating(s)
0 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.93

In the previous week, Dyne Therapeutics had 4 more articles in the media than Solid Biosciences. MarketBeat recorded 7 mentions for Dyne Therapeutics and 3 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.74 beat Dyne Therapeutics' score of 0.19 indicating that Solid Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dyne Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Solid Biosciences
1 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Dyne Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.65, indicating that its stock price is 165% more volatile than the broader market.

Solid Biosciences' return on equity of -66.95% beat Dyne Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Dyne TherapeuticsN/A -69.73% -53.82%
Solid Biosciences N/A -66.95%-58.02%

96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 9.5% of Dyne Therapeutics shares are owned by company insiders. Comparatively, 2.7% of Solid Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Dyne Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dyne TherapeuticsN/AN/A-$446.21M-$3.63N/A
Solid BiosciencesN/AN/A-$174.32M-$1.79N/A

Summary

Solid Biosciences beats Dyne Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Solid Biosciences compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Solid Biosciences (NASDAQ:SLDB) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

In the previous week, Solid Biosciences had 1 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 3 mentions for Solid Biosciences and 2 mentions for Telix Pharmaceuticals. Solid Biosciences' average media sentiment score of 0.74 beat Telix Pharmaceuticals' score of 0.51 indicating that Solid Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Telix Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Solid Biosciences
1 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Telix Pharmaceuticals has higher revenue and earnings than Solid Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Telix Pharmaceuticals$803.79M3.75-$7.12MN/AN/A
Solid BiosciencesN/AN/A-$174.32M-$1.79N/A

Telix Pharmaceuticals' return on equity of 0.00% beat Solid Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Telix PharmaceuticalsN/A N/A N/A
Solid Biosciences N/A -66.95%-58.02%

Telix Pharmaceuticals presently has a consensus price target of $20.50, indicating a potential upside of 131.64%. Solid Biosciences has a consensus price target of $20.00, indicating a potential upside of 221.03%. Given Solid Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Solid Biosciences is more favorable than Telix Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Telix Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Solid Biosciences
1 Sell rating(s)
0 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.93

Telix Pharmaceuticals has a beta of -0.05, meaning that its stock price is 105% less volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.65, meaning that its stock price is 165% more volatile than the broader market.

81.5% of Solid Biosciences shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Solid Biosciences beats Telix Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Solid Biosciences compare to Zai Lab?

Solid Biosciences (NASDAQ:SLDB) and Zai Lab (NASDAQ:ZLAB) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Solid Biosciences has a net margin of 0.00% compared to Zai Lab's net margin of -44.91%. Zai Lab's return on equity of -31.15% beat Solid Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Solid BiosciencesN/A -66.95% -58.02%
Zai Lab -44.91%-31.15%-18.17%

Solid Biosciences presently has a consensus target price of $20.00, indicating a potential upside of 221.03%. Zai Lab has a consensus target price of $37.25, indicating a potential upside of 58.31%. Given Solid Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Solid Biosciences is more favorable than Zai Lab.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Solid Biosciences
1 Sell rating(s)
0 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.93
Zai Lab
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71

Solid Biosciences has a beta of 2.65, suggesting that its share price is 165% more volatile than the broader market. Comparatively, Zai Lab has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

In the previous week, Zai Lab had 10 more articles in the media than Solid Biosciences. MarketBeat recorded 13 mentions for Zai Lab and 3 mentions for Solid Biosciences. Zai Lab's average media sentiment score of 0.75 beat Solid Biosciences' score of 0.74 indicating that Zai Lab is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Solid Biosciences
1 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Zai Lab
5 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

81.5% of Solid Biosciences shares are owned by institutional investors. Comparatively, 41.7% of Zai Lab shares are owned by institutional investors. 2.7% of Solid Biosciences shares are owned by company insiders. Comparatively, 4.9% of Zai Lab shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Solid Biosciences has higher earnings, but lower revenue than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Solid BiosciencesN/AN/A-$174.32M-$1.79N/A
Zai Lab$460.16M6.40-$175.54M-$1.79N/A

Summary

Solid Biosciences beats Zai Lab on 7 of the 13 factors compared between the two stocks.

How does Solid Biosciences compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Solid Biosciences (NASDAQ:SLDB) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

ACADIA Pharmaceuticals has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ACADIA Pharmaceuticals$1.07B2.95$391M$2.118.68
Solid BiosciencesN/AN/A-$174.32M-$1.79N/A

ACADIA Pharmaceuticals has a net margin of 30.13% compared to Solid Biosciences' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 8.90% beat Solid Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
ACADIA Pharmaceuticals30.13% 8.90% 6.86%
Solid Biosciences N/A -66.95%-58.02%

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are held by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 2.7% of Solid Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, ACADIA Pharmaceuticals had 13 more articles in the media than Solid Biosciences. MarketBeat recorded 16 mentions for ACADIA Pharmaceuticals and 3 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.74 beat ACADIA Pharmaceuticals' score of 0.24 indicating that Solid Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ACADIA Pharmaceuticals
5 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Solid Biosciences
1 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

ACADIA Pharmaceuticals has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.65, suggesting that its share price is 165% more volatile than the broader market.

ACADIA Pharmaceuticals currently has a consensus price target of $31.34, suggesting a potential upside of 71.08%. Solid Biosciences has a consensus price target of $20.00, suggesting a potential upside of 221.03%. Given Solid Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Solid Biosciences is more favorable than ACADIA Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ACADIA Pharmaceuticals
0 Sell rating(s)
5 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.72
Solid Biosciences
1 Sell rating(s)
0 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.93

Summary

ACADIA Pharmaceuticals beats Solid Biosciences on 10 of the 15 factors compared between the two stocks.

How does Solid Biosciences compare to IDEAYA Biosciences?

Solid Biosciences (NASDAQ:SLDB) and IDEAYA Biosciences (NASDAQ:IDYA) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

Solid Biosciences currently has a consensus target price of $20.00, indicating a potential upside of 221.03%. IDEAYA Biosciences has a consensus target price of $49.55, indicating a potential upside of 80.82%. Given Solid Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Solid Biosciences is more favorable than IDEAYA Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Solid Biosciences
1 Sell rating(s)
0 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.93
IDEAYA Biosciences
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.80

Solid Biosciences has a net margin of 0.00% compared to IDEAYA Biosciences' net margin of -1,157.18%. IDEAYA Biosciences' return on equity of -39.78% beat Solid Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Solid BiosciencesN/A -66.95% -58.02%
IDEAYA Biosciences -1,157.18%-39.78%-36.25%

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, IDEAYA Biosciences had 11 more articles in the media than Solid Biosciences. MarketBeat recorded 14 mentions for IDEAYA Biosciences and 3 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.74 beat IDEAYA Biosciences' score of 0.34 indicating that Solid Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Solid Biosciences
1 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
IDEAYA Biosciences
1 Very Positive mention(s)
4 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

IDEAYA Biosciences has higher revenue and earnings than Solid Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Solid BiosciencesN/AN/A-$174.32M-$1.79N/A
IDEAYA Biosciences$218.71M12.11-$113.70M-$4.49N/A

Solid Biosciences has a beta of 2.65, suggesting that its share price is 165% more volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of 0.08, suggesting that its share price is 92% less volatile than the broader market.

Summary

IDEAYA Biosciences beats Solid Biosciences on 8 of the 15 factors compared between the two stocks.

Get Solid Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLDB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SLDB vs. The Competition

MetricSolid BiosciencesBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$723.24M$4.06B$7.82B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E RatioN/A25.6832.7626.82
Price / SalesN/A16.068.565.70
Price / CashN/A22.9521.0121.90
Price / Book2.034.184.463.72
Net Income-$174.32M-$24.15M$3.52B$393.10M
7 Day Performance-13.11%-7.25%-5.47%-4.73%
1 Month Performance12.66%-5.98%-4.57%-7.14%
1 Year Performance43.55%-7.72%-1.79%-7.51%

Solid Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SLDB
Solid Biosciences
3.0064 of 5 stars
$6.23
-3.9%
$20.00
+221.0%
+52.8%$723.24MN/AN/A121
DYN
Dyne Therapeutics
3.2054 of 5 stars
$17.01
-5.4%
$31.29
+83.9%
-11.1%$3.37BN/AN/A258
TLX
Telix Pharmaceuticals
4.6336 of 5 stars
$9.36
-3.8%
$20.50
+119.0%
-4.5%$3.31B$803.79MN/A1,184
ZLAB
Zai Lab
3.6286 of 5 stars
$26.04
-1.4%
$37.25
+43.0%
+7.9%$3.31B$460.16MN/A1,784
ACAD
ACADIA Pharmaceuticals
4.7411 of 5 stars
$18.14
-1.3%
$31.55
+73.9%
-22.3%$3.17B$1.07B8.60798

Related Companies and Tools


This page (NASDAQ:SLDB) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners